Thomas Viethen

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.

Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.

Journal: JAMA cardiology

Published: March 26, 2025

An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records.

An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records.

Journal: Cardiology and therapy

Published: February 06, 2025

Asundexian versus Apixaban in Patients with Atrial Fibrillation.

Asundexian versus Apixaban in Patients with Atrial Fibrillation.

Journal: The New England journal of medicine

Published: September 03, 2024

Participant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation: The PEARL-AF Study.

Participant Engagement and Preference Study for Clinical Outcomes Associated With Atrial Fibrillation: The PEARL-AF Study.

Journal: JACC. Advances

Published: June 28, 2024

Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources.

Identification of International Society on Thrombosis and Haemostasis major and clinically relevant non-major bleed events from electronic health records: a novel algorithm to enhance data utilisation from real-world sources.

Journal: International journal of population data science

Published: February 28, 2024

Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.

Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.

Journal: Journal of the American College of Cardiology

Published: August 16, 2023

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Journal: Lancet (London, England)

Published: February 14, 2022

Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP).

Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP).

Journal: NPJ digital medicine

Published: December 23, 2021

Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study.

Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study.

Journal: Journal of cachexia, sarcopenia and muscle

Published: January 16, 2021

Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials.

Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials.

Journal: Digital biomarkers

Published: December 18, 2019

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Journal: JAMA

Published: June 05, 2019

Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial.

Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial.

Journal: Respiration; international review of thoracic diseases

Published: August 13, 2016

Showing 1-12 of 17

Last Updated: 09/26/2026